Jay Panchal

Mr. Jay Panchal

Keele University, Newcastle-under-Lyme, UK
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2022 in Social Sciences
Verified
Journal Article
Open access
PDF file
KPKay Polidano
Kay Polidano
BWBrianne Wenning
Brianne Wenning
ARAlejandra Ruiz-Cadavid
Alejandra Ruiz-Cadavid
BDBaheya Dawaishan
Baheya Dawaishan
JPJay Panchal
Jay Panchal
LDLisa Dikomitis
Lisa Dikomitis
We reviewed the evidence on community-based interventions for the prevention and control of cutaneous leishmaniasis (CL). Community initiatives tailored towards awareness and mobilisation are regarded as a priority area in the Neglected Tropical Disease Roadmap 2021–2030 by the World Health Organization. We searched nine electronic databases for intervention-based studies. Two independent reviewers screened and assessed the articles for methodological quality using predefined criteria. We conducted a meta-analysis using a random effects model, along with narrative synthesis. Thirteen articles were eligible for inclusion, of which 12 were quantitative studies (quasi-experimental with control group and pre-post interventions) and one qualitative study. All articles reported on health education interventions aimed at changing people’s knowledge, attitudes, and practices (KAP) in relation to CL. Participant groups included students, mothers, housewives, volunteer health workers, and residents in general. An increased score was recorded for all outcomes across all interventions: knowledge (SMD: 1.85, 95% CI: 1.23, 2.47), attitudes (SMD: 1.36, 95% CI: 0.56, 2.15), and practices (SMD: 1.73, 95% CI: 0.99, 2.47). Whilst our findings show that educational interventions improved people’s knowledge, attitudes, and practices about CL, we argue that this approach is not sufficient for the prevention and control of this disease. Knowledge does not always translate into action, particularly where other structural barriers exist. Therefore, we recommend the design of more innovative community-based interventions with a broader focus (e.g., stigma, financial barriers, and healthcare access).

1 July 2025 in Open Heart
Verified
Journal Article
Open access
PDF file
ASAlexander James Smith
Alexander James Smith
ACAmy Magaret Munro Cromie
Amy Magaret Munro Cromie
LBLibby Bowles
Libby Bowles
TAThomas Anderson
Thomas Anderson
JPJay Panchal
Jay Panchal
BWBen Walters
Ben Walters
Background: Since the 1960s, beta blockers have been used to treat hypertrophic obstructive cardiomyopathy (HOCM), a genetic disorder causing abnormal heart muscle thickening. This systematic review evaluates their efficacy across clinical outcomes. Methods: Registered on PROSPERO (CRD42022344255), searches were performed in June 2022 and updated in September 2025 across MEDLINE, Embase, CINAHL and PubMed. Two reviewers independently screened studies. Meta-analysis was undertaken when ≥3 comparable datasets were available; otherwise, narrative synthesis was used. Results: 21 studies including 775 adults met inclusion criteria. Beta blockers significantly reduced left ventricular outflow tract (LVOT) gradient (Standardised mean difference (SMD) –1.57; 95% CI –2.07 to –1.07) and heart rate (SMD –1.19; 95% CI –2.24 to –0.14). Sensitivity analyses confirmed the robustness of the LVOT effect, while heart rate effects remained heterogeneous. Improvements in New York Heart Association class, exercise tolerance and symptom burden were consistently reported, although data were subjective and small in scale. Mortality evidence was limited to two retrospective cohorts with divergent findings. Conclusions: Beta blockers provide consistent haemodynamic and symptomatic benefits in HOCM, but most evidence derives from small, older studies with high risk of bias and limited survival data. Contemporary, adequately powered randomised controlled trials are required to define optimal agent selection, dosing and long-term outcomes. PROSPERO registration number: CRD42022344255

26 May 2025 in Journal of Clinical Orthopaedics and Trauma
Verified
Journal Article
Closed access
BMBenjamin Man
Benjamin Man
CRChandramohan Ravichandran
Chandramohan Ravichandran
JPJay Panchal
Jay Panchal
SZShaun Zacharia
Shaun Zacharia
PKPreyeamvadha Ravi Kumar
Preyeamvadha Ravi Kumar
VNVishnu V. Nair
Vishnu V. Nair